NEW YORK (GenomeWeb) – Scipher Medicine of Boston is hoping to develop molecular signatures that can predict a patient's response to autoimmune disease drugs, pushing precision medicine into areas other than oncology.
The company, which was founded in 2014 by researchers at Northeastern University, Harvard, and Brigham and Women's Hospital, uses a proprietary approach for discovering RNA signatures, which it is applying first to predict response to anti-TNF drugs in rheumatoid arthritis and ulcerative colitis.